A modeling study to estimate prostate cancer-specific mortality on active surveillance for men with favorable intermediate-risk prostate cancer: Results from the SEARCH cohort.
Paige K KuhlmannTaofik OyekunleZachary KlaassenChristopher L AmlingWilliam J AronsonMatthew R CooperbergChristopher J KaneMartha K TerrisStephen J FreedlandPublished in: Cancer medicine (2023)
The risk of death for FIR after RP is very low. Assuming even modestly increased PCSM with AS versus RP, the excess risk of death for AS in FIR is low even up to 15 years. These data support the consideration of AS as a relatively safe alternative to RP in FIR men, though prospective randomized trials are needed to validate these findings.